Is colchicine contraindicated in a patient receiving verapamil?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 12, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Colchicine is Contraindicated with Verapamil

Colchicine must not be used in patients taking verapamil due to a life-threatening drug interaction that can cause severe toxicity, multiorgan failure, and death. 1

Mechanism of the Interaction

Verapamil is a moderate CYP3A4 inhibitor and P-glycoprotein inhibitor, both of which are the primary pathways for colchicine metabolism and elimination. 1 When verapamil blocks these pathways, colchicine accumulates to toxic plasma concentrations—increasing colchicine levels by 93-103% according to pharmacokinetic studies. 2, 3

This interaction is explicitly listed in the 2015 ACC/AHA/HRS guidelines as a specific precaution and drug interaction for verapamil, where colchicine is named among the contraindicated or high-risk medications. 1

Clinical Consequences of the Interaction

The combination can precipitate:

  • Severe rhabdomyolysis and myopathy 2, 4
  • Pancytopenia and bone marrow suppression 4, 5
  • Multiorgan failure 4, 1
  • Cardiovascular collapse and cardiac arrhythmias 4, 1
  • Acute renal failure 1, 4
  • Death 1, 4

The EULAR guidelines for Familial Mediterranean Fever explicitly state that concomitant administration of colchicine with verapamil can lead to colchicine toxicity that "can be life threatening" with "no effective means to remove colchicine from the tissues and the blood." 1

What to Do Instead

For Acute Gout Treatment:

  • Use oral corticosteroids (prednisone 0.5 mg/kg/day for 5-10 days, or prednisolone 30-35 mg/day for 3-5 days) as first-line therapy. 3
  • Intra-articular corticosteroid injection for monoarticular or oligoarticular involvement of accessible large joints (e.g., triamcinolone acetonide 40 mg for knee, 20-30 mg for ankle). 3
  • NSAIDs at full FDA-approved doses (naproxen 500 mg twice daily, indomethacin 50 mg three times daily, or sulindac 200 mg twice daily) until complete resolution—but use cautiously if cardiovascular disease, heart failure, or renal impairment is present. 3

For Gout Prophylaxis During Urate-Lowering Therapy:

  • Low-dose NSAIDs with proton pump inhibitor as first-line alternative prophylaxis. 3
  • Low-dose prednisone (<10 mg/day) as second-line prophylaxis option. 3

If Verapamil Can Be Safely Discontinued:

  • Wait at least 14 days after stopping verapamil before initiating colchicine to allow complete clearance of the CYP3A4/P-glycoprotein inhibitor. 3, 4
  • This approach is only feasible if verapamil can be safely stopped and an alternative calcium channel blocker (such as amlodipine, which does not inhibit CYP3A4) or another antihypertensive/antiarrhythmic can be substituted. 4

Common Pitfalls to Avoid

  • Do not attempt dose reduction of colchicine as a "compromise"—even a single 0.6 mg dose carries unacceptable toxicity risk when verapamil is present. 3, 4
  • Do not assume the interaction is only relevant for high-dose colchicine—the interaction affects all colchicine doses, including prophylactic dosing (0.6 mg once or twice daily). 2, 4
  • Do not overlook this interaction in patients with renal impairment—the combination of verapamil plus any degree of renal dysfunction creates exponentially higher risk of fatal colchicine toxicity. 1, 3, 6
  • Do not attribute muscle symptoms solely to statins if the patient is on both colchicine and verapamil—colchicine's independent myotoxic effects or synergistic toxicity may be the culprit. 3, 7, 8

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Treatment of Acute Gout Flares

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Colchicine: a state-of-the-art review.

Pharmacotherapy, 1991

Guideline

Colchicine Use in Chronic Kidney Disease

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.